A Study of OX40L As a Functional Biomarker for Liver Fibrosis


About this study

The primary purpose of this study is to investigate whether the abundance of OX40L expression is associated with the development of hepatic fibrosis.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Subjects who are older than 18 years of age.
  • Subjects who weigh at least 110 pounds (50 kilograms).
  • Subjects who understand that participation is voluntary.
  • Subjects who are able to complete the informed consent process.

Exclusion Criteria: 

  • Subjects who are younger than 18 years of age.
  • Subjects with a medical history of venous thrombosis, angina pectoris, congestive heart failure, or malignant heart disease.
  • Subjects who have a current acute viral, bacterial, or fungal infection.
  • Subjects diagnosed with the Human Immunodeficiency Virus (HIV), or who have tested positive for HIV, documented by any licensed ELISA assay and confirmed by Western Blot procedures at any time prior to donation.
  • Pregnant women.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

SangKon Oh, Ph.D.

Closed for enrollment

Contact information:

Nalani Thomas



More information


Publications are currently not available

Mayo Clinic Footer